garmin

Wellteq Strengthens Collaboration With Garmin to Counter New COVID Surges in the Asia Pacific Region

  • Wellteq (CSE.WTEQ) (OTC.WTEQF) has strengthened its collaboration with Garmin® to offer new enterprise wellness solutions in the Asia Pacific region in response to recent COVID-19 surges.

  • Wellteq's new digital platform focuses on key health indicators to help improve overall wellbeing and increase resistance to COVID-19 with flat-fee, quick-to-launch solutions that include discounted Garmin wearables.

  • Unique to this collaboration, Wellteq will be extending the solution for free to adult family members of employees as many continue to work from the family home.

WellteQ Digital Health Inc. (CSE:WTEQ) (OTC:WTEQF) (the "Company" or "Wellteq") is pleased to announce the Company has strengthened its collaboration with Garmin®, a leading global provider of smartwatches, fitness trackers, and digital health solutions, to offer new enterprise wellness solutions in the Asia Pacific region in response to recent COVID-19 surges. Wellteq's new digital platform focuses on key health indicators to help improve overall wellbeing and increase resistance to COVID-19 with flat-fee, quick-to-launch solutions that include discounted Garmin wearables, free access for adult family members, and availability in multiple languages.

"Wellteq's digital wellness app, integrated with biometric data from Garmin smartwatches and fitness trackers, helps users identify and improve key health indicators that could lead to increased virus resistance. Through a variety of habit-building programs and personalised health and wellness goals, users improve their general physical and mental wellbeing," said Olly Bridge, Chief Growth Officer of Wellteq.

Wellteq's analytics can help identify relationships between quantifiable biometrics such as Body Mass Index and sleeping patterns that may indicate greater risks associated with contracting COVID-19. Available exclusively on Garmin smartwatches 1 , Wellteq's app integrates stress scores, a metric based on heart rate variability, for real time in-app monitoring.

"Garmin is proud to work with Wellteq to offer this valuable resource for companies as they navigate challenges associated with the COVID-19 pandemic," said Karthik Jayaseelan, sales manager for Garmin India. "Wellteq's leading-edge wellness platform leverages sensor data and analytics from Garmin smartwatches and fitness trackers to create a personalized engagement solution that can help people stay healthy and take care of themselves, which is essential at this time."

Family Members Included for Free for First Time

Unique to this collaboration, Wellteq will be extending the solution for free to adult family members of employees, as many continue to work from the family home. The complimentary offer provides broader coverage and wellness benefits to the entire family to promote healthy living and safe physical activity within restrictive environments as many countries go back into or remain in various states of lockdowns.

"Wellteq is proud to extend the impact that we can have with our world-class digital health platform by offering it to spouses for free," Mr. Bridge stated. "The research is clear that the actions and behaviours of our loved ones has a dramatic impact on our own health behaviours, so allowing spouses to share the experience and feel the benefit of our wellness programs is extremely powerful. During difficult times, such as those that the COVID-19 pandemic has brought with it, it is imperative that we support and nudge people to make the right health choices to help maintain their resilience. I can't think of a better company than Garmin to help us with this mission."

The latest Wellteq wellness solution also provides health analytics for HR professionals and senior business leaders across India, Malaysia, Thailand, and Philippines, including:

  • a flat-fee, quick-to-launch solution that includes a discounted Garmin wearable and baseline analytics dashboard for company-wide support and cohort risk evaluation.

  • an unrivalled mobile-first app offered in 13 regional languages.

  • a digital wellness solution that also offers offline solutions as part of Wellteq's extensive global network of partners in fitness, nutrition and physical activity to help keep employees physically active.

1 Garmin wearables are not designed or intended to monitor or diagnose diseases or other conditions.

About Garmin Health

Garmin Health provides custom enterprise business solutions that leverage Garmin's extensive wearable portfolio and high-quality sensor data for applications in the corporate wellness, population health, and patient monitoring markets. As part of a global company that designs, manufactures and ships products worldwide, Garmin Health supports its customers' commerce and logistics needs, allowing enterprises to scale with a single, trusted partner. For more information, visit garmin.com/health , email media.relations@garmin.com , or connect with us at linkedin.com/garmin , twitter.com/garminnews , instagram.com/garminwellness or facebook.com/garmin .

About WellteQ Digital Health Inc.

Wellteq Digital Health Inc. is a leading provider of corporate wellness solutions developed to provide data-driven personalized health and wellness coaching to engage its users in healthier behaviours. As an enterprise (business-to-business) model, Wellteq currently has two main sectors of customers: employers and insurance companies. Wellteq has secured a large multinational portfolio of customers, including UBS, DBS and Bupa Insurance, and reseller partners, like Willis Towers Watson, Advanced Human Imaging and Garmin. Wellteq is developing its newly acquired Internet of Medical Things (IoMT) platform for virtual care applications which will extend the Wellteq continuum of care from preventative wellness through to virtual healthcare.

Wellteq Contact:

Glen Akselrod
Bristol Investor Relations
E: glen@bristolir.com
T: (905) 326-1888
Garmin Health India:

E: karthik.jayaseelan@garmin.com

Garmin Corporate Communications:

E: krista.klaus@garmin.com

Cautionary Note Regarding Forward-Looking Statements:

This news release contains information or statements that constitute "forward-looking statements." Such forward looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements, or developments to differ materially from the anticipated results, performance or achievements expressed or implied by such forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by words such as "expects," "plans," "anticipates," "believes," "intends," "estimates," "projects," "potential" and similar expressions, or that events or conditions "will," "would," "may," "could" or "should" occur.

Forward looking information may include, without limitation, statements regarding the operations, business, financial condition, expected financial results, performance, prospects, opportunities, priorities, targets, goals, ongoing objectives, milestones, strategies and outlook of Wellteq, and includes statements about, among other things, future developments and the future operations, strengths and strategies of Wellteq. Forward-looking information is provided for the purpose of presenting information about management's current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. These statements should not be read as guarantees of future performance or results.

The forward-looking statements made in this news release are based on management's assumptions and analysis and other factors that may be drawn upon by management to form conclusions and make forecasts or projections, including management's experience and assessments of historical trends, current conditions and expected future developments. Although management believes that these assumptions, analyses and assessments are reasonable at the time the statements contained in this news release are made, actual results may differ materially from those projected in any forward-looking statements. Examples of risks and factors that could cause actual results to materially differ from forward-looking statements may include: the timing and unpredictability of regulatory actions; regulatory, legislative, legal or other developments with respect to its operations or business; limited marketing and sales capabilities; early stage of the industry and product development; limited products; reliance on third parties; unfavourable publicity or consumer perception; general economic conditions and financial markets; the impact of increasing competition; the loss of key management personnel; capital requirements and liquidity; access to capital; the timing and amount of capital expenditures; the impact of COVID-19; shifts in the demand for Wellteq's products and the size of the market; patent law reform; patent litigation and intellectual property; conflicts of interest; and general market and economic conditions.

The forward-looking information contained in this news release represents the expectations of Wellteq as of the date of this news release and, accordingly, is subject to change after such date. Readers should not place undue importance on forward-looking information and should not rely upon this information as of any other date. Wellteq undertakes no obligation to update these forward-looking statements in the event that management's beliefs, estimates or opinions, or other factors, should change.

The CSE has neither approved nor disapproved the contents of this news release.



Primary Logo

News Provided by GlobeNewswire via QuoteMedia

The Conversation (0)
  BPH Global Ltd

Notice of Extraordinary General Meeting/Proxy Form

Notice is hereby given that an Extraordinary General Meeting of Shareholders of BPH Global Limited ACN 009 104 330 will be held at 3:00pm AEST on 24 May 2024 at Suite 5, Level 12, 530 Collins Street, Melbourne VIC 3000 (Meeting).

Keep reading...Show less
Genes and chromosomes with "2024" overlay.

Biotech Market Update: Q1 2024 in Review

The first quarter of 2024 witnessed a surge in initial public offerings (IPOs) and mergers and acquisitions (M&A) within the biotech industry, signaling continued interest from investors.

AstraZeneca’s acquisition of start-up Amolyt on March 14, and its longtime biotech partner Fusion Pharmaceuticals for US$2.4 billion on March 19 marked the third acquisition of a radiopharmaceutical developer in recent months. As of writing, there have been 14 M&A deals struck in 2024, according to data from Biopharma Dive.

Investment bank Jefferies released data in early March revealing that the sector was on track to earn its highest quarterly total in three years, reflecting the cautiously optimistic outlook at this year's JPM24 conference.

Keep reading...Show less

AMGEN TO PRESENT TEZSPIRE® PHASE 2A COPD DATA AT ATS 2024

Planning Underway for Phase 3 Development of Tezepelumab in COPD

Amgen (NASDAQ:AMGN) today provided an update regarding the results of the Phase 2a COURSE trial for TEZSPIRE ® (tezepelumab-ekko) in chronic obstructive pulmonary disease (COPD), which were accepted for presentation in the Clinical Trials Symposium at The American Thoracic Society (ATS) 2024 International Conference on Monday, May 20 from 9:15-11:15 a.m. PDT .

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less
Close up 3D rendering of DNA strands.

Biotech Stocks: 5 Biggest Companies in 2024

What are the top biotech companies? The following five stocks have market capitalizations worth billions of dollars and operate in countries all around the globe.

Plus, these big-name biotech players have pipelines stuffed with potentially disruptive products — and enough revenue to recover should some of those products fail.

This means that investors can experience the excitement of biotech investing while minimizing risk. Although returns are never guaranteed, company size can insulate investors from volatility.

Keep reading...Show less
SIRONA BIOCHEM Corporate Update April 2024

SIRONA BIOCHEM Corporate Update April 2024

Sirona Biochem Corp . (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) (" Sirona " or the " Company ") provides the following update:

Dear shareholders,

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Sirona Biochem Announces Close of Private Placement

Sirona Biochem Announces Close of Private Placement

Vancouver, British Columbia – April 4, 2024 Sirona Biochem Corp . (TSX-V: SBM) (Frankfurt: ZSB) (" Sirona ") has closed its private placement (Private Placement") for gross proceeds of $132,500 CAD. The Private Placement consists of 1,325,000 units, (the "Units") at a price of $0.10 per Unit. Each Unit consists of one common share and one transferable share purchase warrant, each whole warrant exercisable into one additional common share of the Company for a period of 2 years from the date of issue at a price of $0.15 per Share in year one and $0.25 per Share in year two. All securities issued under the Private Placement are subject to statutory hold periods expiring on August 4, 2024.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×